Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by Garp1on Feb 09, 2011 7:08pm
345 Views
Post# 18105759

RE: Low closed by JPM manipulators

RE: Low closed by JPM manipulators

Instead of blaming manipulators, it could be time to look at Theratechnologies strategy here.

A possible scenario could be that by allowing the present situation, they can issue options at a much lower price and line-up their pocket when they figure the time will be nice for a secondary offering
 
or stage a takeout bid with their original partner at a much lower price, the way I see the the last partnership it looks like Theratechnologies can sell anytime to its original partner at  which time they can start marketing in Europe without any say from their new partner.

If major shareholders do not want to sell and there are 3.5 million shorted shares, then who is lending those shares to the shorter. Could it be that these shorted shares are being offset by options which are detained by management?

If revenues are starting to come in and with substantial milestone payments and with a cash position of 64 million maybe it's time to institute a share buyback program which would definitely remove some of the cheap shares on the market. If money is ever needed in the future a secondary offering could then take place at a more suitable price.

Where did you ever see or read Theratechnologies commitment to protect shareholder value and how they would go about protecting it?

Before we set JPM as a manipulator maybe we should look at who are the participants in that game and what their vested interest are.

 

Bullboard Posts